Protein Globule Formation in the Liver Graft during Cold Preservation for Liver Transplantation: Its Clinical and Pathological Significance

Changyin Feng, Tongmei He, Haijian Huang, Lijuan Qu, Yi Jiang, Wenhua Zhang, Zhiyong Zheng

.
Department of Pathology, Dongfang Hospital, Fujian Medical University, Fuzhou, China.

DOI: 10.4236/ojpathology.2013.33022                

Abstract

In liver transplantation, liver graft ischemia-reperfusion injury occurs mainly due to cold preservation and warm reperfusion. In this research, we study the affection of plasma protein of the donor on liver graft during cold preservation and warm reperfusion. In this study, 34 liver transplantations were performed from 2007 to 2010, and the clinical data were collected retrospectively from the Dongfang Hospital database. 34 specimens were harvested from 34 liver grafts when graft trimming as Group A and 34 specimens harvested from the same 34 liver grafts during liver transplantation surgery but before abdominal closure as B group. All liver tissue specimens were fixed with 40 g/L neutral formalin, embedded in paraffin. Light microscopy, transmission electron microscopy, Periodic Acid-Schiff (PAS) stain and immunohistochemical stain of IgG, IgM, IgA, C3d, C4d, Fib, C1q, and CD61 were used. In this study, we found that eosinophilic bodies emerged in liver lobes during liver transplantation which had not been reported previously in the literature. 1) Protein globules were found exclusively in liver graft specimens. The globules were round or oval with sharp edges, measured approximately 1.59 to 9.41 μm in diameter, and were scattered in the liver sinusoids or space of Disse or hepatocyte cytoplasm, were stained with IgG, IgM, IgA, Fib, C3d by immunohistochemical staining; 2) There was no statistical significant difference of protein globules number between A group and B group (P > 0.05); 3) IRI score of B group was not correlated with protein globules number (P > 0.05). Protein globules contain plasma composition, and may form during cold preservation.

Keywords

Hepatitis B Virus; Immunohistochemistry; Liver Transplantation; Liver Ischemia-Reperfusion Injury

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	S. J. Zhang, C. J. Zhu, Y. F. Zhao, J. Li and W. Z. Guo, “Different Ischemic Preconditioning for Rat Liver Graft: Protection and Mechanism,” Hepatobiliary & Pancreatic Diseases International, Vol. 2, No. 4, 2003, pp. 509-512.
[2]	S. Yan, L. M. Jin, Y. X. Liu, L. Zhou, H. Y. Xie and S. S. Zheng, “Outcomes and Mechanisms of Ischemic Preconditioning in Liver Transplantation,” Hepatobiliary & Pancreatic Diseases International, Vol. 9, No. 4, 2010, pp. 346-354.
[3]	H. Shimizu, M. Miyazaki, H. Ito, K. Nakagawa, S. Ambiru, A. Kato, et al., “Mechanism of Cold Ischemia-Reperfusion Induced Graft Injury after Orthotopic Liver Transplantation in Rats,” Hepatogastroenterology, Vol. 48, No. 37, 2001, pp. 216-219.
[4]	J. W. Kupiec-Weglinski and R. W. Busuttil, “Ischemia and Reperfusion Injury in Liver Transplantation,” Transplantation Proceedings, Vol. 37, No. 4, 2005, pp. 1653-1656. doi:10.1016/j.transproceed.2005.03.134
[5]	C. Y. Feng, “Research on Humoral and Cellular Immune Markes of Liverg Graft before and after Reperfusion,” Master’s Thesis, Fujian Medical University, Fuzhou, 2009. http://epub.cnki.net/grid2008/brief/detailj.aspx?filename=2009150523.nh&dbname=CMFD2009
[6]	T. E. Starzl, C. Miller, B. Broznick and L. Makowka, “An Improved Technique for Multiple Organ Harvesting,” Surgery, Gynecology & Obstetrics, Vol. 165, No. 4, 1987, pp. 343-348.
[7]	X. N. Feng, X. Xu and S. S. Zheng, “Current Status and Perspective of Liver Preservation Solutions,” Hepatobiliary & Pancreatic Diseases International, Vol. 5, No. 4, 2006, pp. 490-494.
[8]	Y. Calmus, “Immunosuppression after Liver Transplantation,” La Presse Médicale, Vol. 38, No. 9, 2009, pp. 1307-1313. doi:10.1016/j.lpm.2009.06.004
[9]	Y. H. Yu and Z. Y. Zheng, “Color Atlas of Renal Biopsy Pathology,” Fujian Science and Technology Press, Fuzhou, 2008.
[10]	W.-M. Cong, “The Guide for Pathological Diagnosis and Classification of Common Disease after Liver Transplantation (I),” Chinese Journal of Organ Transplantation, 2008, pp. 49-51.
[11]	W.-M. Cong, “The Guide for Pathological Diagnosis and Classification of Common Disease after Liver Transplantation (II),” Chinese Journal of Organ Transplantation, 2009, pp. 690-691.
[12]	N. S. Goldstein, J. Hart and K. J. Lewin, “Diffuse Heap-Tocyte Ballooning in Liver Biopsies from Orthotopic Liver Transplant Patients,” Histopathology, Vol. 18, No. 4, 1991, pp. 331-338. doi:10.1111/j.1365-2559.1991.tb00854.x
[13]	L. Luo, Y. Chen and X.-L. Ji, “Clinicopathological Observation and Analysis of Donor Liver and Biopsy in Liver Transplantation,” Chinese Journal of Hepatobiliary Surgery, Vol. 15, No. 12, 2009, pp. 885-887.
[14]	J. F. McManus, “Histological and Histochemical Uses of Periodic Acid,” Stain Technology, Vol. 23, No. 3, 1948, pp. 99-108.
[15]	J. A. Chasis and S. B. Shohet, “Red Cell Biochemical Anatomy and Membrane Properties,” Annual Review of Physiology, Vol. 49, 1987, pp. 237-248. doi:10.1146/annurev.ph.49.030187.001321
[16]	T. Ihara, T. Yamamoto, M. Sugamata, et al., “The Process of Ultrastructural Changes from Nuclei to Apoptotic Body,” Virchows Archiv, Vol. 433, No. 5, 1998, pp. 443-447. doi:10.1007/s004280050272
[17]	S. H. Kim and H. J. Jeong, “Glomerular C4d Deposition Indicates in Situ Classic Complement Pathway Activation, but Is Not a Marker for Lupus Nephritis Activity,” Yonsei Medical Journal, Vol. 44, No. 1, 2003, pp. 75-80.
[18]	X. Bu, Z. Zheng, Y. Yu, L. Zeng and Y. Jiang, “Significance of C4d Deposition in the Diagnosis of Rejection after Liver Transplantation,” Transplantation Proceedings, Vol. 38, No. 5, 2006; pp. 1418-1421. doi:10.1016/j.transproceed.2006.03.018
[19]	X. Bu, Z. Zheng, C. Wang and Y. Yu, “Significance of C4d Deposition in the Follicular Lymphoma and MALT Lymphoma and Their Relationship with Follicular Dendritic Cells,” Pathology—Research and Practice, Vol. 203, No. 3, 2007, pp. 163-167. doi:10.1016/j.prp.2006.11.004
[20]	X. Ding, Z.-Y. Zheng, C. Wang, L. Zeng and Y. Jiang, “ABO-Incompatible Liver Transplantation: A Pathological Analysis of 2 Cases,” World Chinese Journal of Digestology, 2008, pp. 2056-2060.
[21]	K. Murata and W. M. Baldwin 3rd, “Mechanisms of Complement Activation, C4d Deposition, and Their Contribution to the Pathogenesis of Antibody-Mediated Rejection,” Transplantation Reviews (Orlando), Vol. 23, No. 3, 2009, pp. 139-150. doi:10.1016/j.trre.2009.02.005
[22]	P. S. Hair, J. Q. Gronemus, K. B. Crawford, V. P. Salvi, K. M. Cunnion, N. M. Thielens, et al., “Human Astrovirus Coat Protein Binds C1q and MBL and Inhibits the Classical and Lectin Pathways of Complement Activation,” Molecular Immunology, Vol. 47, No. 4, 2010, pp. 792-798. doi:10.1016/j.molimm.2009.10.006
[23]	L. A. Tan, B. Yu, F. C. Sim, U. Kishore and R. B. Sim, “Complement Activation by Phospholipids: The Interplay of Factor H and C1q,” Protein Cell, Vol. 1, No. 11, 2010, pp. 1033-1049.
[24]	L. T. Roumenina, M. Radanova, B. P. Atanasov, K. T. Popov, S. V. Kaveri, S. Lacroix-Desmazes, et al., “Heme Interacts with c1q and Inhibits the Classical Complement Pathway,” The Journal of Biological Chemistry, Vol. 286, No. 18, 2011, pp. 16459-16469. doi:10.1074/jbc.M110.206136
[25]	A. Mateo, C. O. Pintado, J. P. de la Lastra, R. Dusinsky, M. Simon, J. Naessens, et al., “Ruminant Cluster CD41/ CD61,” Veterinary Immunology and Immunopathology, Vol. 52, No. 4, 1996, pp. 251-253. doi:10.1016/0165-2427(96)05570-5
[26]	A. Merono, C. Lucena, A. López, J. J. Garrido, L. L. de Pérez and D. Llanes, “Immunohistochemical Analysis of Beta3 Integrin (CD61): Expression in Pig Tissues and Human Tumors,” Histology and Histopathology, Vol. 17, No. 2, 2002, pp. 347-352.
[27]	C. Fondevila, R. W. Busuttil and J. W. Kupiec-Weglinski, “Hepatic Ischemia/Reperfusion Injury—A Fresh Look,” Experimental and Molecular Pathology, Vol. 72, No. 4, 2003, pp. 86-93. doi:10.1016/S0014-4800(03)00008-X
[28]	T. Okazaki, A. Nakahashi, T. Uchiyama, A. Imoto, K. Morikawa, T. Okano, et al., “Composition of Cryoglobulin and Cryoprecipitate,” Clinical Chemistry and Laboratory Medicine, Vol. 47, No. 9, 2009, pp. 1161-1163.
[29]	J. S. Davidson, “Appropriate Cryoglobulin Investigations,” Annals of Clinical Biochemistry, Vol. 47, No. 5, 2010, p. 491. doi:10.1258/acb.2010.010088
[30]	G. Motyckova and M. Murali, “Laboratory Testing for Cryoglobulins,” American Journal of Hematology, Vol. 86, No. 6, 2011, pp. 500-502. doi:10.1002/ajh.22023
[31]	Chapter 2, “Anatomy and Physiology of the Liver. Arjan van der Plaats. The Groningen Hypothermic Liver Perfusion System for Improved Preservation in Organ Transplantation,” 2005. http://dissertations.ub.rug.nl/FILES/faculties/medicine/2005/a.van.der.plaats/c2.pdf
[32]	H. F. Eggink, N. Hofstee, C. H. Gips, R. A. Krom and H. J. Houthoff, “Histopathology of Serial Graft Biopsies from Liver Transplant Recipients,” American Journal of Pathology, Vol. 114, No. 1, 1984, pp. 18-31.
[33]	T. Inagaki, S. Kobayashi, N. Ozeki, M. Suzuki, Y. Fukuzawa, K. Shimizu, et al., “Ultrastructural Identification of Light Microscopic Giant Mitochondria in Alcoholic Liver Disease,” Hepatology, Vol. 15, No. 1, 1992, pp. 46-53. doi:10.1002/hep.1840150110
[34]	P. Fickert, M. Trauner, A. Fuchsbichler, C. Stumptner, K. Zatloukal and H. Denk, “Mallory Body Formation in Primary Biliary Cirrhosis Is Associated with Increased Amounts and Abnormal Phosphorylation and Ubiquitination of Cytokeratins,” Journal of Hepatology, Vol. 38, No. 4, 2003, pp. 387-394. doi:10.1016/S0168-8278(02)00439-7
[35]	H. Denk, C. Stumptner, A. Fuchsbichler and K. Zatloukal, “Alcoholic and Non-Alcoholic Steatohepatitis,” Verhandlungen der Deutschen Gesellschaft für Pathologie, 2005, pp. 137-143.
[36]	Z. Schaff and P. Nagy, “Novel Factors Playing a Role in the Pathomechanism of Diffuse Liver Diseases: Apoptosis and Hepatic Stem Cells,” Orvosi Hetilap, Vol. 145, No. 35, 2004, pp. 1787-1793.
[37]	W. S. Moon, H. C. Yu, M. J. Chung, M. J. Kang and D. G. Lee, “Pale Bodies in Hepatocellular Carcinoma,” Journal of Korean Medical Science, Vol. 15, No. 5, 2000, pp. 516-520.
[38]	J. A. Burrows, L. K. Willis and D. H. Perlmutter, “Chemical Chaperones Mediate Increased Secretion of Mutant Alpha 1-Antitrypsin (alpha 1-AT) Z: A Potential Pharmacological Strategy for Prevention of Liver Injury and Emphysema in Alpha 1-AT Deficiency,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 97, No. 4, 2000, pp. 1796-1801. doi:10.1073/pnas.97.4.1796
[39]	P. Gómez-Garre, E. Gutiérrez-Delicado, C. Gómez-Abad, J. Morales-Corraliza, V. E. Villanueva and S. R. de Córdoba, “Hepatic Disease as the First Manifestation of Progressive Myoclonus Epilepsy of Lafora,” Neurology, Vol. 68, No. 17, 2007, pp. 1369-1373. doi:10.1212/01.wnl.0000260061.37559.67